Papp, Kim A.
Gooderham, Melinda
Lynde, Charles
Brassard, Danielle
Al-Mohammedi, Faisal
Prajapati, Vimal H.
Delorme, Isabelle
Albrecht, Lorne
Haydey, Richard
Alam, Maryam Shayesteh
Beecker, Jennifer
Siddha, Sanjay
Maguin, Marie
Farag, Mahmoud S.
Vieira, Antonio
Rihakova, Lenka
Langley, Richard G.
Funding for this research was provided by:
Novartis Pharmaceuticals AG and led by Novartis Pharmaceuticals Canada.
Article History
Received: 28 March 2024
Revised: 28 March 2024
Accepted: 26 April 2024
First Online: 8 June 2024
Declarations
:
: All patients provided informed consent to participate in the study. The study design was reviewed and approved by the ethics committees or institutional review boards, and the study was conducted in accordance with the principle of the Declaration of Helsinki.
: Kim A. Papp serves as a consultant for AbbVie, Akros, Amgen, Arcutis, Atellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Can-Fite Biopharma, Coherus, Dermavant, Dermira, Dow Pharma, Eli Lilly and Company, Evelo, Galapagos, Galderma, Genentech, Incyte, Janssen, Kyowa Hakko Kirin, Leo Pharma A/S, Merck (MSD), Merck Serono, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Takeda and UCB; received research grants from Anacor, Gilead, GSK, MedImmune, Moberg Pharma and Sun Pharmaceuticals; is a scientific officer for Akros, Anacor, Arcutis, Dice Pharmaceuticals and Kyowa Hakko Kirin; is a consultant for Dice Pharmaceuticals, Meiji Seika Pharma and Mitsubishi Pharma; is a speaker, received honoraria and participated in steering committees and advisory boards for AbbVie, Amgen, Bausch Health/Valeant, Celgene, Eli Lilly and Company, Janssen, Merck (MSD), Novartis, Pfizer and Sanofi-Aventis/Genzyme. Melinda Gooderham serves as a speaker, an investigator or an advisory board member for AbbVie, Amgen, Akros, Arcutis, Arena, Aslan, AnaptysBio, Apogee, Aristea, Bausch, Boehringer Ingelheim, BMS, Celgene, Coherus, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Meiji, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, Union, UCB and Ventyx. Charles Lynde serves as a speaker or consultant or advisor or investigator or received honoraria from AbbVie, Altius, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Devonian, Eli Lilly, Fresnius Kabi, Galderma, GSK, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L’Oreal, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, TEVA, Tribute, UCB, Valeant, Viatris, Volo Health. Danielle Brassard is a speaker and receives honoraria from AbbVie, Actelion, Bausch Health, Galderma, Janssen, Leo Pharma, Novartis, Pfizer and Sanofi; participates as a consultant for AbbVie, Amgen, Bausch Health, Celgene, Novartis and Pfizer; and acts as principal investigator for AbbVie, BMS, Bausch Health, Incyte, Leo Pharma, Novartis, Pfizer, Reistone and Sanofi. Faisal Al-Mohammedi is an investigator for Novartis, Jansen, Bausch, Abbvie and Incyte Pharma.Vimal H. Prajapati is an investigator for AbbVie, Amgen, AnaptysBio, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma, and Valeant; has served as a consultant, advisor and/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, CorEvitas, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, Janssen, LEO Pharma, L’Oreal, Medexus, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB Pharma, and Valeant; received grants from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Antonio Vieira and is a full-time employee at Novartis Pharmaceuticals Canada Inc. and Lenka Rihakova was a full-time employee at Novartis Pharmaceuticals Canada Inc. until final draft of this manuscript. Isabelle Delorme serves as a speaker or consultant, or received honoraria from Abbvie, Bausch Health, Amgen, Eli Lilly, Novartis, and Janssen. Lorne Albrecht serves as a speaker or consultant or advisor or investigator or received honoraria/grants from AbbVie; Amgen; Arcutis; Bausch Health; Bristol-Myers-Squibb; Celgene; Eli Lilly; Galderma; Janssen; LEO Pharma; Novartis; Pfizer; Sanofi; UCB. Richard Haydey has been a consultant and advisor and/or received speaking fees and/or grants and/or served as an investigator in clinical trials for the following companies: AbbVie, Amgen, Galderma, GSK, Leo, Lilly, Novartis, Merck, Pfizer, UCB and consulting fees from AbbVie, Amgen, Janssen, Galderma, GSK, Leo, Lilly, Novartis, Pfizer, Bausch-Health, Celgene and UCB. Maryam Shayesteh Alam have no conflict of interest. Jennifer Beecker serves as a consultant for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Sun Pharma, and UCB; is a speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Sun Pharma, and UCB; and received research grants from AbbVie, Amgen, Concert, Evelo, Incyte, Janssen, Leo Pharma, Novartis, Janssen, Leo Pharma, Novartis. Sanjay Siddha serves as an investigator for AbbVie, Amgen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, LEO Pharma, has served as a consultant, advisor and/or speaker for AbbVie, Actelion, Amgen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, LEO Pharma, L’Oreal, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB Pharma, and Valeant; received grants from Amgen, Astellas. Marie Maguin, Mahmoud S. Farag and Antonio Vierra are a full-time employee at Novartis Pharmaceuticals Canada Inc. Lenka Rihakova was a full-time employee at Novartis Pharmaceuticals Canada Inc. until the initial draft development of this manuscript. Richard Langley serves as an investigator, advisory board member, or speaker for AbbVie, Amgen, Bausch, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galderma, GSK, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharmaceuticals, and UCB.